MaxCyte (NASDAQ: MXCT) shares preliminary 2025 results press release

Rhea-AI Filing Summary

MaxCyte, Inc. reported that it has released preliminary unaudited financial results for the quarter and fiscal year ended December 31, 2025. The company furnished a press release dated January 12, 2026 as Exhibit 99.1 to a current report on Form 8-K under the item covering results of operations and financial condition. The information in this section and the exhibit is being furnished, not filed, so it is not subject to certain Exchange Act liabilities and is not automatically incorporated by reference into other securities law filings.

0001287098false00012870982026-01-122026-01-12

​

​

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

​

​

FORM 8-K

​

CURRENT REPORT

Pursuant to Section 13 or 15(d) of

The Securities Exchange Act of 1934

​

Date of Report (Date of earliest event reported): January 12, 2026

​

​

MaxCyte, Inc.

(Exact name of registrant as specified in its charter)

​

​	​	​	​	​
Delaware	​ ​ ​	001-40674	​ ​ ​	52-2210438
(State or other jurisdiction of incorporation)	​	(Commission File Number)	​	(IRS Employer Identification No.)

​

9713 Key West Avenue, Suite 400

Rockville, Maryland 20850

(Address of principal executive offices, including zip code)

​

(301) 944-1700

(Registrant’s telephone number, including area code)

​

N/A

(Former name or former address, if changed since last report)

​

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

​

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

​

Securities registered pursuant to Section 12(b) of the Act:

​

​	​	​	​	​
Title of each class	​ ​ ​	Trading Symbol(s)	​ ​ ​	Name of each exchange on which registered
Common Stock, $0.01 par value	​	MXCT	​	The Nasdaq Stock Market LLC

​

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

​

Emerging growth company    ☒

​

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial account standards provided pursuant to Section 13(a) of the Exchange Act. ☐

​

​

​

​

Item 2.02. Results of Operations and Financial Condition.

​

On January 12, 2026, MaxCyte, Inc. (the “Company”) issued a press release announcing preliminary unaudited financial results for the quarter and fiscal year ended December 31, 2025. A copy of this press release is attached as Exhibit 99.1 to this Current Report on Form 8-K.

​

In accordance with General Instructions B.2. of Form 8-K, the information in this Item 2.02 and Exhibit 99.1 hereto, is furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) or otherwise subject to the liabilities of that section. The information contained herein and in the accompanying exhibit is not incorporated by reference in any filing of the Company under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof and irrespective of any general incorporation language in any filings, except as expressly set forth by specific reference in such a filing.

​

Item 9.01. Financial Statements and Exhibits.

​

(d) Exhibits

​

Exhibit Number	​ ​ ​	Exhibit Description
​	​	​
99.1	​	Press Release, dated January 12, 2026
104	​	Cover Page Interactive Data (embedded within the Inline XBRL document)

​

​

​

​

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

​

​	​	​
​	MaxCyte, Inc.
​	​
Dated: January 12, 2026	By:	/s/ Douglas Swirsky
​	​	Douglas Swirsky
​	​	Chief Financial Officer

​

​

​

FAQ

What did MaxCyte (MXCT) disclose in this Form 8-K?

MaxCyte, Inc. furnished a Form 8-K to announce that it issued a press release with preliminary unaudited financial results for the quarter and fiscal year ended December 31, 2025.

Which period do MaxCyte (MXCT)'s preliminary results cover?

The preliminary unaudited financial results relate to MaxCyte’s quarter and fiscal year ended December 31, 2025.

How were MaxCyte (MXCT)'s preliminary results communicated to investors?

The results were communicated through a press release dated January 12, 2026, which is attached to the Form 8-K as Exhibit 99.1.

Are MaxCyte (MXCT)'s preliminary results audited?

No. The company describes the disclosed figures as preliminary unaudited financial results for the relevant quarter and fiscal year.

Is the information in MaxCyte (MXCT)'s Form 8-K considered filed with the SEC?

No. The company states that the information in Item 2.02 and Exhibit 99.1 is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Exchange Act.

Who signed the MaxCyte (MXCT) Form 8-K for the company?

The Form 8-K was signed on behalf of MaxCyte, Inc. by Douglas Swirsky, who is identified as the company’s Chief Financial Officer.